Ofatumumab
Arzerra, Kesimpta (ofatumumab) is an antibody pharmaceutical. Ofatumumab was first approved as Arzerra on 2009-10-26. It is used to treat lymphoid leukemia in the USA. It has been approved in Europe to treat relapsing-remitting multiple sclerosis. The pharmaceutical is active against B-lymphocyte antigen CD20.
Trade Name | Kesimpta |
---|---|
Common Name | Ofatumumab |
Indication | lymphoid leukemia, relapsing-remitting multiple sclerosis |
Drug Class | Monoclonal antibodies |
